| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2800937801019 | 93780101 | ADRIBLASTINA PS.INJ.SOL 10MG/VIAL ΒΤx1 VIAL+1 AMPx5 ML | 4.84 | 05.08 | 7.00 |
| 05/2018 | 2800937803013 | 93780301 | ADRIBLASTINA PD.INJ.SOL 50MG/VIAL ΒΤx1 VIAL | 11.48 | 12.05 | 16.61 |
| 05/2018 | 2800937804010 | 93780401 | ADRIBLASTINA INJ.SOL 10MG/5ML VIAL ΒΤx1VIAL | 4.84 | 05.08 | 7.00 |
| 05/2018 | 2800937806014 | 93780601 | ADRIBLASTINA INJ.SOL 50MG/25ML VIAL ΒΤx1VIAL | 11.48 | 12.05 | 16.61 |
For the treatment of Koposi's sarcome connected to AIDS.
Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
LD<sub>50</sub>=21800 ug/kg (rat, subcutaneous)
55 hours
Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.
* 324-809 mL/min/m2 * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]